EATONTOWN, N.J., June 18, 2014 (GLOBE NEWSWIRE) -- American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has entered into initial agreements with the nanoRANCH Division of UHV Technologies, Inc. ("nanoRANCH") for the development of methods for the delivery of therapeutics and drugs focused upon cancer treatments utilizing adipose derived adult stem cells. The Company will be working with Dan Dimitrijevich, PhD to create new treatment delivery methods utilizing a combination of nanoRANCH unique technology and CRYO's clinically processed ATCELLs™.
The Company's research collaboration into cancer research and cancer related applications utilizing CRYO's clinically processed ATCELL™ products further expands relationships and potential applications to treat a wide range of diseases in the growing regenerative and therapeutic cellular therapy markets.
"We are noticing a sharp increase in demand for our cutting edge clinically prepared cells and ancillary products for use in scientific development." said Anthony Dudzinski, "further we believe that the repeatable results that can be achieved with our ATCELL™ products are important to the development of the comparative data necessary to advance the use of adipose derived stem cells in regenerative medicine and cellular therapies."
"Accurate targeting of pharmaceuticals is a continuing hurdle in drug delivery and particularly important are selectivity and specificity of anticancer agents." According to Dr. Dan Dimitrijevich of nanoRANCH, "There is much to be learned from the trafficking and homing properties of immune system cells and stem cells as they navigate through the body. We are very fortunate to have available from American CryoStem, ATCELL™, well defined and characterized stem cells that will serve as an excellent model system."
About UHV Technologies
UHV Technologies is a, high-tech nanotechnology company focused on the development of advanced materials and devices, including vacuum coating equipment, carbon nanotube coatings, nanocrystalline coatings, fiber optical coating, nano-material-based devices, and nano-biotechnology devices. Recently, UHV's other division nanoXRF merged with MICROMATTER of Vancouver, BC to become the leading supplier of X-Ray fluorescence calibration standards for air pollution monitoring and diamond foils for applications in particle and accelerator physics including cyclotrons used for production of radiopharmaceuticals used in radiation therapy of cancer patients. Over the past several years, UHV has been developing X-ray fluorescence spectrometry for biological applications specifically as it pertains to cancer diagnoses and determination of cancer progression. Currently, UHV is funded by US Department of Energy with three separate R&D contracts related to XRF technology for developing products for high speed automated aluminum alloy scrap sorting, continuous monitoring of mercury emissions from coal power plants, and nano-crystalline foils for DOE's high energy physics labs as well commercial applications in low energy x-ray windows. For more information, please visit www.nanoRANCH.com, www.nanoXRF.com and www.micromatter.com.
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem is a developer, marketer and global licensor of patented adipose tissue based cellular technologies and related proprietary services with a focus on clinical processing, commercial bio-banking and application development for adipose (fat) tissue and autologous adipose-derived regenerative cells (ADRCs). The Company maintains a strategic portfolio of intellectual property and patent applications that form its Adipose Tissue Processing Platform, which supports and promotes a growing pipeline of biologic products and processes, clinical services and international licensing opportunities. Through its ACS Laboratories division, the Company operates an FDA registered, cGMP compliant human tissue processing, cryo-storage and cell culture and differentiation media development facility in Mount Laurel, New Jersey. For more information, please visit www.americancryostem.com and www.acslaboratories.com.